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HNTRODUCTION
Graft-versus-host disease (GVHD), lymphopenia,
nd immune deﬁciency are major complications of
llogeneic hematopoietic stem cell transplantation and
re causes of morbidity and mortality [1,2]. Immune
uppression (IS) therapy administered for control of
VHD, injury to the thymus occurring during con-
itioning and GVHD, and decreased thymus-depen-
ent lymphopoiesis in older patients are major con-
ributors to delayed immune reconstitution. GVHD is
nitiated by donor T cells responding to alloantigen
ither minor histocompatibility antigens or major his-
ocompatibility determinants in the case of HLA-mis-
atched transplants [3,4]. Clinical GVHD occurs
hen a sufﬁcient number of host-reactive donor T
ells are activated and achieve sustainable effector
unctions despite administration of prophylactic IS
herapy. Standard GVHD prophylaxis usually consists
f a calcineurin inhibitor together with methotrexate
r mycophenolic acid. Despite the best empirical pro-
hylaxis therapy, clinically signiﬁcant GVHD requiring
dditional immune suppression therapy occurs in 40%
o 80% of transplantations (HLA matched and mis-
atched). A recent analysis of Seattle data has docu-
ented that approximately 50% ofHLA-matched trans-
lant patients who receive combined prophylaxis therapy
an be successfully withdrawn from all IS within 2 years;
owever, 20% of patients may remain IS dependent for
years or longer [5].
The incidence, severity, and time of onset of acute
VHD are determined by the degree of disparity, as
ell as the number and afﬁnity of host-reactive donor
-cell receptors speciﬁc for host alloantigen. A kinetic
odel of GVHD predicts that clinical disease is prob-
ble when the frequency of host-reactive T cells
eaches a critical threshold. Detailed quantitative un- c
4erstanding of the variables that affect alloreactivity
nd the clinical syndromes we recognize as acute and
hronic GVHD remain subjects of active clinical re-
earch.
ONOR T-CELL ACTIVATION AND ALLOREACTIVITY
FTER TRANSPLANTATION
The expression of HLA-DR by peripheral blood
cells, as well as other markers such as CD25 and
D38, is evidence of T-cell activation. Early after
ransplantation, the frequency of DR T cells is
reater in unrelated donor and HLA-mismatched
ransplants than matched sibling donor (MSD) trans-
lants and is greater in patients who develop acute
VHD. DR T cells peak before the onset of acute
VHD. The numbers of T cells and DR T cells
ecrease dramatically after the administration of glu-
ocorticosteroids for treatment of GVHD. Levels of
R T cells remain lower in patients who are free of
linical GVHD, but they can remain increased above
ormal levels for several months after transplantation.
CTIVATION-INDUCED CELL DEATH
Programmed cell death, or apoptosis, plays an
mportant role in lymphocyte homeostasis. Recent
tudies have demonstrated an increase in apoptotic T
ells in peripheral blood and increased apoptosis dur-
ng short-term in vitro culture [6]. At 18 to 21 days
fter transplantation, apoptosis occurs among 50% to
0% of CD3 T cells during 24 hours of culture.
evels of apoptosis are higher in patients with acute
VHD and patients who receive transplants from
LA-mismatched donors. CD4 cells are more sus-
eptible to apoptosis than CD8 cells, whereas
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BD3/CD56 natural killer cells are resistant. HLA-
R and CD45ROCD4 cells are more likely to
ndergo apoptosis than HLA-DR/CD25 and
LA-DR/CD45RA cells. The level of apoptosis
arly after hematopoietic stem cell transplantation
orrelates with lymphopenia and delayed recovery of
D4 counts. These results are consistent with the
ypotheses that T cells activated by host alloantigen
ndergo clonal deletion and that a strong persistent
lloreaction contributes to lymphopenia.
HANGES IN T CELLS AFTER TREATMENT OF GVHD
Administration of glucocorticosteroids (steroids)
or the treatment of GVHD induces lymphopenia and
educes the number of apoptotic T cells in the periph-
ral blood. The reduction in apoptotic cells is sus-
ained in steroid responders, but DR apoptosis-
rone T cells reappear in patients whose steroid
reatment fails.
N VITRO INDUCTION OF APOPTOSIS WITH
LUCOCORTICOSTEROID AND ANTI-CD3
ONOCLONAL ANTIBODY
T cells from patients with acute GVHD are more
usceptible to dexamethasone-induced and CD3-in-
uced apoptosis in vitro than T cells from patients
ithout GVHD. Dexamethasone and anti-CD3 anti-
ody induce apoptosis preferentially among DR or
D38 activated T cells, whereas T cells that express
D25 are relatively resistant. Sensitivity to dexameth-
sone is lost in GVHD patients who become resistant
o glucocorticosteroid therapy, but T cells from ste-
oid-resistant patients remain sensitive to CD3-in-
uced apoptosis. Sensitivity to CD3-induced apopto-
is may have utility as a predictor of patients likely to
xperience treatment failure with steroid treatment or
o become steroid resistant to GVHD. This approach
o assessing alloreactivity and response to GVHD
reatment may provide an objective indicator for early
ntervention with alternate GVHD treatment.
HANGES IN HOST-REACTIVE T-CELL ACTIVITY
To understand the changes in host reactivity that
ccur after transplantation, we monitored host-reac-
ive T-cell responses by using a limiting dilution assay
n a longitudinal study. The frequency of both cyto-
oxic T cells and interleukin (IL)–2–secreting helper
cells was assayed in HLA MSD and matched unre-
ated donor (MURD) transplants. As expected, the
retransplantation donor-versus-recipient cytotoxic
-lymphocyte precursor (CTLp) frequency was sig-
iﬁcantly higher for MURD (32 CTLp/106 CD3ells) than for HLA-identical sibling pairs (9 CTLp/ C
B & M T06 CD3 cells). Host-reactive T-cell frequencies
niformly increased during the ﬁrst 90 days after
ransplantation. The magnitude of response was
quivalent for MSD and MURD recipients (median
TLp at 3 months after transplantation, 54 and 53
TLp/106 CD3 cells). However, at 1 year after
ransplantation, the median CTLp for MSD trans-
lants (41/106 CD3 cells) was signiﬁcantly lower
P .01) than for MURD transplants (106/106 CD3
ells). At 1 year, signiﬁcant decreases in CTLp were
bserved in 9 of 12 MSD transplants, but CTLp in
URD transplants continued to increase during the
rst year and then peaked after year 1. A signiﬁcant
ecrease in MURD transplants occurred during the
econd year in 9 of 10 cases. A decrease in anti–host
-cell activity generally correlated with a reduction of
mmune suppression therapy, but CTLp levels above
aseline were also observed in a few patients who
emained GVHD free after withdrawal from all im-
une suppression.
NALYSIS OF GENE EXPRESSION AFTER
EMATOPOIETIC CELL TRANSPLANTATION:
EW APPROACH TO MONITORING ALLOREACTIVITY
Serial blood samples were obtained from a cohort
f 50 patients every 2 to 3 weeks after transplantation
hrough day 100 and immediately before the admin-
stration of steroids for treatment of acute GVHD,
nd complementary DNA was prepared from freshly
solated RNA for gene array experiments. Patients
reated for acute GVHD who survived at least 180
ays were categorized according to steroid response:
1) complete response, (2) steroid dependence, and (3)
reatment failure (ie, progressive GVHD).
Initial experiments were aimed at assessing global
ene expression in blood leucocytes collected from pa-
ients early after transplantation with the Affymetrix
2000 gene chip [7]. Studies with samples obtained at
ay 21 demonstrated a massive alteration in gene expres-
ion. Signiﬁcant changes were identiﬁed in 1176 genes
mong 15 patients compared with 10 normal controls. A
elatively small number of genes from among the 1176
dentiﬁed were predictive of acute GVHD in 8 of the 15
atients who developed acute GVHD within 1 week
day 21-28) compared with the other 7 patients, who
emained free of GVHD for at least 90 days. Only 7
enes from the 1176 were associated with development
f clinical GVHD (3 increased and 6 decreased expres-
ion). Subsequent experiments focused on longitudinal
aired comparisons for individual patients comparing
ene expression at 2 time points before the onset of
VHD. Eight patients were studied at 18 to 21 days and
8 days after transplantation. Four of these patients de-
eloped acute GVHD within the following week.
hanges preceding the onset of GVHD were detected
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2n 143 genes (in 3 of the 4 patients). Among the 55 genes
hat showed increased expression, 4 were associated with
daptive immunity and 6 with inﬂammation. Among the
8 showing decreased expression, 3 were associated with
ell metabolism, 6 with DNA repair and cell cycle, 5
ith signal transduction, and 10 with adaptive immunity.
hese seemingly paradoxical changes suggest a signiﬁ-
ant shutdown of blood leucocyte function with the
nset of GVHD, a ﬁnding that correlates with other
vents such as T-cell activation, activation-induced cell
eath, and lymphopenia, all of which occur during the
nset of GVHD. Further gene expression studies are
eeded to get a more complete picture of the cellular
vents associated with GVHD. Our preliminary data
ndicate that these changes will be complex and that the
ist of candidate genes will have to remain relatively large
ntil sufﬁcient data are available to identify relevant and
obust marker genes for each of the pathways that may
e relevant to the various components of alloreactivity,
VHD, and tolerance.
ELEVANCE OF POLYMORPHISMS IN IMMUNE
ESPONSE GENES
Nucleotide variation in the promoter and coding
egions of immune response genes, including cyto-
ines and cytokine receptors, has been associated with
ltered function that affects immune response, inﬂam-
ation, and susceptibility to disease [8-12]. We have
ested for single nucleotide polymorphisms (SNPs) in
everal immune response genes, but our most substan-
ial effort to date has focused on elucidating the role of
L-10 in the allograft reaction and GVHD [13].
HE IL-10 PATHWAY
Our initial studies involved the identiﬁcation of
NPs in 5 cytokine and cytokine receptor genes in
SD transplants. The study population was sepa-
ated into 2 cohorts. Cohort 1 (570 cases) was des-
gnated the training set for screening IL-1b, IL-
RA, IL-6, IL-10, transforming growth factor, and
NFA. The strongest association with severe grade
II to IV acute GVHD and nonrelapse mortality was
een for the IL-10/-592 SNP. This preliminary
nding was conﬁrmed in a second cohort of 423
SD transplants. A multivariate analysis was per-
ormed in the combined cohort of 993 cases. The
robability of severe GVHD was 23.4% for the
592 CC genotype compared with 11.5% for the AA
enotype (odds ratio, 2.01; P  .003). The proba-
ility of nonrelapse mortality was 29% for the -592
C genotype compared with 17% for the AA ge-
otype (odds ratio, 1.84; P  .09). Subsequent stud-
es have focused on another member of the IL-10
athway, the gene encoding the IL-10  chain re-
6eptor (IL-10RB). Studies in the same cohort of 993
SD transplants revealed that the IL-10RB/1304
enotype of the donor was also independently asso-
iated with the severity of acute GVHD. When the
L-10/-592 AA genotype was considered together
ith IL-10RB/1304 GG genotype, an additive pro-
ective effect was observed. Among the 993 donor-
ecipient pairs studied, none of the 16 cases with a
atient IL-10 A/A genotype and donor IL-10RB
/G genotype developed grades III to IV acute
VHD.
UMMARY
Profound changes occur among lymphocytes after
ransplantation. Alloreactivity induces T-cell activa-
ion and clonal proliferation. Multiple factors are
robably capable of inﬂuencing the strength and sus-
ainability of alloreactivity. Activation-induced cell
eath is a prominent feature of acute GVHD, but the
ltimate severity and duration of GVHD is deter-
ined by the number of host-reactive T-cell clones
hat escape activation-induced cell death and survive
s mature T cells. Alternatively, conditions promoting
more effective activation-induced cell death should
acilitate tolerance. Persistent activation-induced cell
eath can also have a downside by prolonging lym-
hopenia and thereby delaying immune reconstitu-
ion. Studies in experimental models have shown that
-cell activation can also induce nonspeciﬁc apoptosis
nd that this kind of collateral damage can impair
ormal lymphocyte homeostasis and is greatly affected
y the allograft reaction and associated injury to thy-
us and possibly by other critical elements of the
ymphoid microenvironment.
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